LGND - High Risk High Return - Ligand Has 100% Upside
Ligand Pharmaceuticals (LGND) share price has fallen more than 50% since September, and on January 16, Citron Research published a report questioning the credibility of Ligand's pipeline data and optimism, which led to another sharp decline of the share price. However, the share price recovered in the two trading days that followed.
Citron's research report sparked new concerns over the future profitability of Ligand, but I believe investors need to pay close attention to these new developments as there might be an investment opportunity around the corner if the pipeline turns out to be solid.